17th International Myeloma Workshop 2019

17th International Myeloma Workshop - Boston 2019

Thank you!

To all our local organizers, IMS leadership, faculty, presenters, attendees, and sponsors, thank you for making the 17th International Myeloma Workshop (IMW) a great success!

Over 3200 registered delegates attended the 17th IMW, the largest in the history of the workshop. In addition to 150 invited faculty, over 600 study abstracts were presented at the 17th IMW in oral and poster sessions, including 150 from young investigators.

Congratulations to the 40 young investigators who were honored at the 17th IMW, and to Professor Giampaolo Merlini who received the Jan Gosta Waldenstrom Award for lifetime contributions to myeloma; Dr. Constantine Mitisades who received the Kenneth C. Anderson Young Investigator Award for Basic and Translational Research; and Dr. Francesca Gay who received the Bart Barlogie Young Investigator Award for Therapeutics.

The 18th IMW will be held September 8-11, 2021, in Vienna, Austria under the auspices of professors Heinz Ludwig, Hermann Einsele, Hartmut Goldschmidt and Roman Hajek. More information on the 18th IMW will be forthcoming at https://www.myelomasociety.org/

Steve Treon, Paul Richardson, Ken Anderson, Nikhil Munshi
and all the organizers of the 17th IMW

POSTER SESSION I - FRIDAY, SEPTEMBER 13, 2019 - 6:30 to 8:00 PM - HYNES AUDITORIUM

POSTER SESSION II - SATURDAY, SEPTEMBER 14, 2019 - 12:30 to 2:00 PM – HYNES AUDITORIUM

Multiple Myeloma Genomics

Multiple Myeloma Genomics - Poster Session I

Abstract Number	Poster Presentation	Lead Author
FP-039	Long-term Follow-up of Clonal Evolutions of Myeloma Cells in the Bone Marrow	Yuko Shirouchi
FP-033	Effect of t(11;14) on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the ConnectÂ® MM Registry	Cristina J. Gasparetto
FP-010	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact	James Chim
FP-044	Large deletions (>10.9 MB) in 17p and bi-allelic TP53 inactivation events in newly-diagnosed multiple myeloma are associated with higher clonal cell fraction and poor prognosis	Fadi Towfic
FP-018	MicroRNA analysis in multiple myeloma and extramedullary disease	Jana Gregorova
FP-046	IgH translocations with undefined partners are associated with superior outcome in multiple myeloma patients	xuehan Mao
FP-047	Multiple high-risk cytogenetic aberrations confer a progressively negative impact on survivals of newly diagnosed myeloma patients	xuehan Mao
FP-013	Plasma Cell-free DNA chromosomal instability score as early predictor to monitor tumor burden in response to therapeutic in multiple myeloma patients	Juan Du
FP-005	Mate pair sequencing outperforms fluorescence in situ hybridization and improves diagnostic yield in the genomic characterization of multiple myeloma	Linda Baughn
FP-015	Next-generation optical mapping reveals numerous previously unrecognizable structural variants in multiple myeloma	Regina Fillerova
FP-031	The three-dimensional (3D) spatial distribution of lamin A/C in the nuclei of Myeloma Cells	Aline Pozzo
FP-050	CD24 Is a Phenotypic Marker and a Potential Therapeutic Target for Multiple Myeloma Tumor-Initiating Cells	Fenghuang Zhan
FP-006	Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma	Bachisio Ziccheddu
359	Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study	Mattia D'Agostino
FP-037	The contribution of proteasome subunits to Myeloma cell viability and proteasome inhibitor sensitivity	Chang-Xin Shi
FP-034	Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the ConnectÂ® MM Registry	Sikander Ailawadhi
431	Utilisation of liquid biopsies in functional high-risk myeloma demonstrates a unique mutational pattern and extensive spatial heterogeneity	Andrew Spencer
FP-041	DNA-repair gene mutations are prevalent in circulating tumour DNA from advanced multiple myeloma patients	Andrew Spencer
FP-028	Aminopeptidase gene expression in myeloma	Nina Nupponen
FP-048*	The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed /refractory multiple myeloma	Jing Xu
FP-003	DNA methylation reprogramming in relapsed/refractory myeloma converges with loci prognostic of survival in newly diagnosed patients	Benjamin Barwick
FP-008	Clinicopathologic characteristics and clinical outcome of multiple myeloma with del(17p): A retrospective analysis of single center experience for 12 years.	Heejung Chae
FP-029	Whole-genome bisulfite sequencing identifies HDAC3-mediated DNA methylation in multiple myeloma	Daisuke Ogiya
FP-009	Validation of SKY92 high and low risk prognostication in a retrospective, multinational cohort of 155 non-trial multiple myeloma patients	Yan-Ting Chen
FP-002	Aberrations of chromosome X in patients with multiple myeloma	Jana Balcarkova
FP-042	A COMPREHENSIVE SERUM MICRORNA PROFILING IN INDIAN MULTIPLE MYELOMA PATIENTS UNIFORMLY TREATED WITH VCD-PROTOCOL	Harshini Sriram
FP-023	IGH and IGK Rearrangement and IGH Somatic Hypermutation Analysis Using Next-generation Sequencing for the Detection of Clonality in High-risk Korean Multiple Myeloma Patients	Miyoung Kim
FP-012	The prognostic value of 1q21 gain does not rely on the copy numbers, clone size and concurrence with t(4;14)	Chenxing Du
FP-025	A Maturation Index defines Newly Diagnosed Multiple Myeloma Patients with advanced immunophenotypic and Molecular Differentiation profiles associated with poor prognosis	Marina Martello
FP-036	Gain of Chromosome 1q is Associated with Early Progression in Multiple Myeloma Patients Treated with Lenalidomide, Bortezomib, and Dexamethasone	Timothy Schmidt
FP-014	L-type amino-acid transporter 1 (LAT1) expression is predictive of response to autologous stem cell transplantation for multiple myeloma	Mark Fiala
FP-035	Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis	Vishesh Sarin
FP-021	Super-enhancer profiling of multiple myeloma in search of novel oncogenes and therapeutic targets	Yunlu Jia
FP-022	The adverse double-hit effect of combining cytogenetic abnormalities and ISS stage III on the outcome of patients with newly-diagnosed multiple myeloma	Fengyan Jin
FP-026	Loss of TRIM33 in Multiple Myeloma correlates with increased genomic instability	Roisin McAvera
FP-040	Rare, but complex chromosomal rearrangements, defined 'Chromoanagenesisâ€, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients	Vincenza Solli
FP-027	Dysregulation of HUWE1 is associated with an increased mutational burden in Multiple Myeloma	Jonathan Morgan
FP-049	Feasibility study to establish diagnostic biomarkers for relapsed refractory multiple myeloma	Hiroshi Yasui
FP-019	DETERMINATION OF CNVs BY NGS BASED DIGITAL MLPA IN MULTIPLE MYELOMA AND THEIR EFFECT ON CLINICAL OUTCOME	Ritu Gupta
FP-020	Inferring Biological Pathways in Multiple Myeloma after Missing Value Imputation	Gurvinder Kaur
FP-030	VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma	Andrea Poletti
FP-016	Fusion gene detection across a large cohort of multiple myeloma patients	Steven Foltz
FP-011	Circulating cell free DNA is a biomarker for GEP70 risk score and tumor burden in myeloma	Shayu Deshpande
FP-045	Enrichment for copy number alterations and a unique pattern of gene mutations characterize multiple myeloma in elderly patients	Louis Williams
FP-017	Defining the differentiation states of multiple myeloma at single cell resolution â€“ Identifying opportunities for immunotherapy	Julia Frede
801	Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma	Raphael Szalat
FP-004	A detailed exploration of using RNA-Seq data in established multiple myeloma gene expression profile microarray based risk scores	Michael Bauer
FP-007	Long-term Analysis Of Multiple Sequential Samples Reveals Patterns Of Progression In Smoldering Myeloma	Eileen Boyle
FP-001	The CureCloud Research Initiative, a Next-Gen Direct-To-Patient Clinico-Immuno-Genomic Registry	Daniel Auclair
FP-032	Epigenetic regulation of gene expression in progression of multiple myeloma	Mahshid Rahmat
FP-043	ABL kinase inhibitor increases cytotoxicity of chemotherapeutic agents while reducing/inhibiting genomic instability in multiple myeloma	Subodh Kumar
FP-038	CRISPR-based functional genomics landscape of genes recurrently mutated in MM	Ricardo de Matos Simoes
FP-024	Delineating association between polymorphic variants of vitamin D receptor (VDR) gene and multiple myeloma disease in Indian population.	Raman Kumar

Multiple Myeloma Microenvironment

Multiple Myeloma Microenvironment - Poster Session I

Abstract Number	Poster Presentation	Lead Author
207	Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Micro-Environment (TIME) of Multiple Myeloma (MM)	Cristina PÃ©rez Ruiz
228	Utilization of Microscopy to Inform and Generate a Patient-Specific, 3D Model of Multiple Myeloma	Katrina Harmon
232	The bone marrow microenvironment of multiple myeloma promotes myeloma related anemia by suppressing the differentiation of hematopoietic stem cells	lanting liu
257	IMMUNE PROFILING OF PLASMA CELL DYSCRASIAS REVEALS A THERAPY RELATED T-CELL MODULATION IN MULTIPLE MYELOMA PATIENTS.	Gregorio BarilÃ
266	Macrophages as a potential therapeutic target: Clodronate-liposome treatment inhibits multiple myeloma tumour establishment in vivo	Khatora Opperman
288	The impact of lactate dehydrogenase (LDH) in association with the International Staging System (ISS) on patients with multiple myeloma.	Maricy LOPES
299	Activated and Bone-marrow Resident Treg Alterations Underlie Malignant Transformation from MGUS to Multiple Myeloma	Slavica Vuckovic
319	Enhanced lipid accumulation and metabolism are required for the differentiation and activity of tumor-associated macrophages in multiple myeloma	Pan Su
329	Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination in the bone marrow	David Fooksman
339	Bone marrow Ki67 staining is prognostic for survival in newly diagnosed multiple myeloma	Shebli Atrash
347	Modeling tumor microenvironment interactions of IMID sensitive and resistant cells in 3D organotypic culture models	Aarif Ahsan
356	Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy	Hua Yan
387	A prospective study of circulating chemokines and angiogenesis markers and risk of multiple myeloma and its precursor	Jonathan Hofmann
393	Investigation of the relationship between obesity, weight cycling, and tumor progression in a myeloma xenograft model	Heather Fairfield Campbell
394	A New â€˜Vicious Cycleâ€™: Bidirectional Interactions Between Myeloma Cells and Adipocytes	Heather Fairfield Campbell
410	The combination of complement 1q and its receptor gC1qR could promote the proliferation of plasma cells through IGF2BP3 in multiple myeloma patients with 1q21 amplification	Jiadai Xu
447	PD-1 blockade reinvigorates bone marrow CD8+ T cells from patients with multiple myeloma in the presence of TGF-Î² inhibitors.	Yoon Seok Choi
511	Excessive abdominal fat content indicates poor prognosis in patients with newly diagnosed multiple myeloma	Li Bao
558	Mesenchymal Stromal Cell Sialylation Modulates Antitumor Immune Responses In Multiple Myeloma	Kevin Lynch
596	A Hematopoietic Score Predicts Survival in Newly Diagnosed Multiple Myeloma Patients.	Abdullah S. Al Saleh
628	Cell surface glucose-regulated protein 78 (GRP78) is upregulated in plasma cells of patients with multiple myeloma compared to monoclonal gammopathy of uncertain significance	Slavisa Ninkovic
658	TLR4 signaling drives mesenchymal stromal cells (MSC) commitment to promote tumor microenvironment transformation in multiple myeloma	Cesarina Giallongo
690	A Highly Reproducible 3D Culture Approach for Functional Drug Testing on Primary Multiple Myeloma Cells.	Victor Peperzak
703	Mass cytometry reveals increase in marrow resident monocytes associated with response to daratumumab and pomalidomide	Oliver Van Oekelen
706	Syndecan-1 and stromal HSPGs: key moderators of communication between myeloma plasma cells and the bone marrow niche	Steven Pals
750	Endothelial Progenitor Cells as Drug Delivery Trojan Horses for Theranostic Use in Multiple Myeloma	Barbara Muz
758	FlowCT: A semi-automated workflow for deconvolution of immunophenotypic data and objective reporting on large datasets	Catarina Maia
778	Macrophages promote DNA repair of double strand break in multiple myeloma cells by non-homologous end joining(NHEJ), nevertheless sacrifice the accuracy of NHEJ	zhen cai
789	Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma	Tommaso Perini
824	Targeting bone marrow adipose tissue and the FABP family increases efficacy of dexamethasone in MM	Mariah Farrell

Multiple Myeloma Signaling

Multiple Myeloma Signaling - Poster Session I

Abstract Number	Poster Presentation	Lead Author
267	The study on the expression of long noncoding RNA in multiple myeloma with extramedullary disease	Xiaoyan Qu
355	CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma	Li Bao
361	INCREASED EXPRESSION OF PD-1 CHECKPOINT MOLECULE ON BONE MARROW T-CELLS FROM PATIENTS WITH MULTIPLE MYELOMA: POTENTIAL IMPACT ON CLINICAL OUTCOME ?.	Pablo Perez-Montero
377	Next Generation Proteomics and Drug Sensitivity Resistance Testing Allow for the Identification of Distinct Sub-clones of Multiple Myeloma Patients	Despina Bazou
422	CD28 Mediates Pro-Survival Autophagy In Multiple Myeloma	Peng Peng
436	Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma	Fan Zhou
439	Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy	Takeshi Harada
465	Blocking of WIP1 Phosphatase Overcomes Bortezomib Resistance and Promotes Cell Death via ER Stress-induced Apoptotic JNK/c-Jun Signaling: Novel Therapeutic Target in Multiple Myeloma	Katia Beider
518	Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options	Steven Pals
539	Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-induced ER Stress and Cell Death via HSP70 and LAMP3 Down-regulation: Novel Therapeutic Target for Multiple Myeloma	Katia Beider
548	ILF2 antisense oligonucleotide therapy and CRISPR/Cas9-based screening for DNA repair effectors identify synthetic lethal approaches to enhancing myeloma cellsâ€™ sensitivity to DNA damage	Natthakan Thongon
557	Roundabout 1 (ROBO1) Mediates Multiple Myeloma Survival and Interaction with the Bone Marrow Microenvironment	Giada Bianchi
561	A progressive auto-amplification loop in TAK1 expression and activation in myeloma cells	Jumpei Teramachi
622	YWHAE/14-3-3Îµ expression impacts the proteasome load contributing to proteasome inhibitor sensitivity in multiple myeloma	Yan Xu
626	Downregulation of the unfolded protein response is a potential mechanism for therapeutic resistance in multiple myeloma	Scott Goldsmith
720	Functional proteogenomic screens in multiple myeloma	Ryan Young
782	RNF6 promotes myeloma cell proliferation and survival by stabilizing and activating glucocorticoid receptor	Xinliang Mao
786	Dexamethasone synergizes with MCL-1 inhibition in multiple myeloma through suppression of S6 phosphorylation	Ingrid Spaan
800	In vivo modeling of clonal competition using CRISPR-based gene editing reveals novel fitness variables in multiple myeloma	Yujia Shen
803	Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma	Eugenio Morelli
826	Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy	Judith Lind

Multiple Myeloma Novel Agents

Multiple Myeloma Novel Agents - Poster Session I

Abstract Number	Poster Presentation	Lead Author
421	The first-in-class BMI-1 modulators PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma	Arnold Bolomsky
425	Ex vivo sensitivity to venetoclax is predictive of clinical activity	Cecilia Bonolo de Campos
434	Risk of Renal Toxicities with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials	Somedeb Ball
459	Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity	Panagiotis Efentakis
502	Nursing implications for multiple myeloma patients undergoing chimeric antigen receptor (CAR) T-cell therapy.	Erika Florendo
566	A Phase I study of PNK-007, allogeneic, off the shelf NK cell, post autologous transplant in multiple myeloma (NCT02955550)	Sarah Holstein
568	Chidamide, a novel histone deacetylase inhibitor, suppresses myeloma proliferation via inhibiting proteasome activity and ASH2L gene expression	Yunyan Zan
582	Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study	MARIA GAVRIATOPOULOU
592	Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study	Dan T. Vogl
608	Synergistic Drug Combinations to Overcome Venetoclax Resistance in Multiple Myeloma	Nathalie Meurice
614	TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNÎ±) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo	Marjan Fatholahi
617	Efficacy and Safety of Selinexor for Heavily Pretreated Multiple Myeloma Treatment â€“ A Systematic Review	Muhammad Junaid Tariq
637	Proteasome inhibition by Carfilzomib, but not by Bortezomib, induces a specific, proteasome subunit-dependent impairment in cardiac contractility.	Max Mendez
644	Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma	Christie Verkleij
648	A murine reactive version of TAK-573 (anti-CD38-targeted attenuated IFNÎ± fusion protein) shows immunomodulatory and anti-tumor activity in an immunocompetent murine tumor model	Mingying Bi
712	Prognostic value and clinical correlations of serum cereblon (CRBN) levels in multiple myeloma patients treated with Lenalidomide/Dexamethasone (RD).	Annita Ioanna Gkioka
736	Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in Multiple Myeloma	Katie Ryan
866	Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)	Robert Cornell

Multiple Myeloma Novel Drug Targets

Multiple Myeloma Novel Drug Targets - Poster Session I

Abstract Number	Poster Presentation	Lead Author
152	KDM5A reinforces MYC transcriptional program and promotes myeloma cell growth	Hiroto Ohguchi
231	DNp73 promotes the proliferation and drug resistance of multiple myeloma	Jie Xu
274	MIF acting as a chaperone of SOD1 mediates MM cell intrinsic resistance to carfilzomib by modulating ROS-induced mitochondrial dysfunction	Qiang Wang
296	TAZ functions as a tumour suppressor in multiple myeloma by downregulating MYC	Stacy Grieve
304	ATR addiction in Multiple Myeloma: synthetic lethal approaches exploiting established therapies	Giovanni Tonon
358	Salsalate is An Active Agent in Multiple Myeloma	Cinnie Yentia Soekojo
398	Targeting Ubiquitin Receptor Rpn13/ADRM1 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity	Arghya Ray
402	Inhibition of Ubiquitin Receptor PSMD4/Rpn10 as Therapeutic Strategy to Overcomes Bortezomib-Resistance in Multiple Myeloma cells	Yan Song
423	A Small Molecule-induced Targeted Degradation of Ubiquitin Receptor Rpn13 as a Novel Therapeutic Strategy in Multiple Myeloma	Yan Song
467	Immunosuppressive adenosine - a novel treatment target for multiple myeloma	Rui Yang
484	Downregulation of methylation and demethylation enzymes in unsorted cell population of multiple myeloma patients	Katerina Smesny Trtkova
527	Nelfinavir interacts with mitochondrial VDACs and disrupts oxidative phosphorylation in proteasome inhibitor resistant myeloma	Andrej Besse
534	Synergistic targeting of Sp1 in myeloma cells with hyperthermia plus proteasome inhibitors	Hirokazu Miki
544	Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma	Jorge Contreras
553	Infectious complications following Venetoclax-Proteasome Inhibitor based regimens in relapsed myeloma: a single center retrospective analysis	Luca Bernabei
560	Preclinical evaluation of tropolone and proteasome inhibitor therapy for multiple myeloma	Sarah Holstein
623	Aberrant RHAMM (receptor for hyaluronan-mediated motility) splicing in MM is associated with upregulation of PTBP1/2 (polypyrimidine tract binding protein 1/2): therapeutic implications	Daisuke Ogiya
639	Panobinostat (LBH589) in combination with the Î²-catenin inhibitor Tegavivint (BC2059) exerts significant anti-myeloma activity both in vitro and in vivo	Andrew Spencer
682	N-glycan Analysis from Monoclonal IgG in Patients with Multiple Myeloma Enables Differentiation of Disease States	Giao Le
694	MAGE-A3 mediates survival and proliferation through regulation of BIM and p21Cip1 in multiple myeloma	Hearn Jay Cho
723	Protein Synthesis Rates Regulate Tumor-initiating Potential and Chemoresistance in Multiple Myeloma	Eun-Hee Park
726	Treatment of RAS-Mutated Multiple Myeloma by Targeting MAP4K2	Shirong Li
733	CD200 expressing multiple myeloma cells show increased resistance against T cell-mediated cytotoxicity	Pooja Shah
739	Functional characterization of the RAL-dependent survival pathway in multiple myeloma	Marcel Seibold
796	HDAC8 Mediates Homologous Recombination and Cytoskeleton Integrity in Myeloma with Potential Impact on Cell Growth and Survival	Maria Gkotzamanidou
807	Inhibition of the JAK-STAT3-Mcl-1 Axis by Combining Ruxolitinib with S63845 Completely Prevents Plasmacytoma Growth in the Gp130-Regulated INA-6 Xenograft Mouse Model	Renate Burger
863	E2 ubiquitin conjugase UBE2T contributes to genome maintenance through homologous recombination in multiple myeloma	David Alagpulinsa
874	CDK4/6 Inhibition Suppresses Myeloma Cell Growth and Viability via Perturbation of E2F Proliferative Program	Chandraditya Chakraborty

Antibody Based Approaches to MM

Antibody Based Approaches to MM - Poster Session I

Abstract Number	Poster Presentation	Lead Author
141	The impact of neonatal FcRn receptor-mediated recycling on the kinetics of daratumumab in multiple myeloma	Felicity Kendrick
258	QIP-MS: An alternative to electrophoresis to distinguish endogenous M-proteins from therapeutic monoclonal antibodies in multiple myeloma	Oscar Berlanga
284	Inhibition of CD47 as a Novel Cancer Immunotherapy for Multiple Myeloma	Jennifer Sun
300	Targeting stromal-derived Gremlin1 to control Multiple Myeloma disease development	Kimberley Clark
311	LONG TERM SAFETY AND EFFICACY OF DARATUMUMAB RAPID INTRAVENOUS INFUSION (90 MINUTES) AFTER THE THIRD DOSE IN MULTIPLE MYELOMA PATIENTS	Alessandro Gozzetti
321	Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma	Sung-Soo Yoon
324	'Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study.â€	Rafael RÃos Tamayo
338	Safety of rapid daratumumab infusion in relapsed and refractory multiple myeloma	Elisabetta Antonioli
340	M-Protein semi-quantification in MM serum patients based on Immuno-Capture and Liquid Chromatography coupled to High Resolution Mass Spectrometry	StÃ©phane Muccio
351	MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma	Yu-Tzu Tai
354	Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): First results of the GMMG-CONCEPT trial	Anne Marie Asemissen
412	CLINICAL CHARACTERISTICS AND TRANSFUSION MANAGEMENT OF PATIENTS DIAGNOSED OF MULTIPLE MYELOMA RECEIVING DARATUMUMAB: EXPERIENCE OF A SINGLE CENTRE	Mario Arnao
442	Therapeutic Antibody as Interference for identification of endogenous monoclonal proteins-Three Clinical Cases	Gabriel Bryk
509	Practice Patterns with Focal Progression on Daratumumab Therapy	Susan Bal
555	EVALUATION OF CD319 (SLAMF7) AS A NOVEL GATING MARKER FOR PLASMA CELLS IN FLOW CYTOMETRIC IMMUNOPHENOTYPING OF MULTIPLE MYELOMA	Harshini Sriram
605	Daratumumab induces mechanisms of immune activation through CD38+NK cell targeting.	Ada Dona
609	Durability of Response and Characterisation of Corneal events with Extended follow-up after Belantamab Mafodotin monotherapy for patients with relapsed/refractory Multiple Myeloma	Rakesh Popat
629	DNA methyltransferase inhibitors upregulate CD38 expression and enhance daratumumab efficacy in multiple myeloma	Priya Choudhry
697	HDP-101, a Novel BCMA-targeted Antibody Conjugated to Î±-Amanitin, is Active against Myeloma with Preferential Efficacy against Pre-clinical Models of Deletion 17p	Ram Kumar Singh
715	Efficacy and safety of a modified daratumumab/bortezomib/dexamethasone regimen using once weekly bortezomib in relapsed refractory multiple myeloma	Marin Abousaud
718	Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)	Ajai Chari
734	Patient tolerability and Estimation of Direct/Productivity costs associated with rapid infusion of daratumumab.	Issam Hamadeh
737	CD84: A Potential Novel Therapeutic Target in the Multiple Myeloma Microenvironment	Emine Gulsen Gunes
755	Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients	Edvan de Queiroz CrusoÃ©
867	CD46 Antibody Drug Conjugate Impedes Myeloma Engraftment in Patient-Derived Xenografts	Michael VanWyngarden
876	Manual polybrene (MP), not dithiothreitol (DTT), is the recommended method for blood banking procedure in myeloma patients treated with anti-CD38 monoclonal antibody in Asia	Su-Peng Yeh

Immunotherapeutic Approaches to MM

Immunotherapeutic Approaches to MM - Poster Session I

Abstract Number	Poster Presentation	Lead Author
176	Super-resolution microscopy reveals ultra-low expression of CD19 on myeloma cells that triggers elimination by CAR-T cells	Thomas Nerreter
187	Immunotherapy in Multiple Myeloma: Boom or Bust? Investigating Oligoclonal Banding and Survival in Multiple Myeloma Patients Receiving Anti CD3-CD28 Co-Stimulated and Engineered Autologous T cells after Autologous Stem Cell Transplant.	Dina Ioffe
223	Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study	Meletios A. Dimopoulos
256	Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma	Je-Jung Lee
265	Frequent methylation of the tumor suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification	Lu Qian Wang
278	DART4MM: DARATUMUMAB AS CONSOLIDATION THERAPY IN PATIENTS WHO ALREADY ACHIEVED OPTIMAL RESPONSE /MRD POSITIVITY BY NEXT GENERATION FLOW (NGF): PRELIMINARY RESULTS OF A PHASE 2 MULTICENTER STUDY	Alessandro Gozzetti
297	Hypersialylation protects Myeloma cells from NK cell mediated killing and this can be overcome by targeted desialylation using a sialyltransferase inhibitor.	John Daly
373	A novel antiCD38-CAR construct increases the in vitro responsiveness of NK cells against Multiple Myeloma cells	Maria Karvouni
376	Combination of herpes-simplex based oncolytic viruses (HSV-OV) with natural killer (NK) cells in Multiple Myeloma	Katharina Helene Susek
391	Inhibition of Kynurenine-3-Monooxygenase in Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Myeloma Immunity	Arghya Ray
413	Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma	Xiaohu (Frank) Fan
428	Preclinical evaluation of CD8+ Anti-BCMA mRNA CAR T-Cells for control of multiple myeloma	Liang Lin
470	CS1 Targeted Chimeric Antigen Receptors (CAR) for treatment of multiple myeloma (MM)	Julie O'Neal
514	PD-L1 expression in bone marrow plasma cells as a biomarker to predict prognosis of newly diagnosed multiple myeloma patients: development of a nomogram-based prognostic model	Byung-Hyun Lee
575	Mechanisms, biologic sequelae and clinical benefits of bortezomib-induced immunogenic cell death in multiple myeloma	Annamaria GullÃ
583	Novel RNA construct increases cytotoxic proteins in lymphocytes and leads to prolonged survival in an experimental syngeneic immunocompetent Multiple Myeloma model	Arnika Kathleen Wagner
602	Reinstating anti-tumor activity of Natural Killer cells	Ceyda Caliskan
621	Neoantigen-specific CD4+ T cells induce protective, tumor-specific CD8+ T cells in a mouse model of multiple myeloma.	Selma Bekri
687	Novel On-Target Restoration of a Split T Cell-Engaging Antibody for Precision Immunotherapy of Multiple Myeloma	Thomas Bumm
729	Ruxolitinib (RUX) reverses checkpoint inhibition by downregulating PD-L1 expression in both multiple myeloma (MM) tumor and stromal cells	Haiming Chen
741	CD38 and CD45 expression on plasma cells and response to daratumumab in Multiple Myeloma	Eline Lammers
748	Nanoparticle Multi-Specific T cell Engagers for the Treatment of Multiple Myeloma	Kinan Alhallak
756	Lenalidomide (Len) Refractory MM Patientsâ€™ Outcomes	Annita Ioanna Gkioka
838	Modulation of NK, T, & B cell sub-populations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma.	Prabhal Rao
875	Molecular markers of MM cell sensitivity and resistance to Natural Killer cells: implications for anti-MM immunotherapy	Sara Gandolfi

Myeloma Response Assessment including MRD

Myeloma Response Assessment including MRD - Poster Session I

Abstract Number	Poster Presentation	Lead Author
144	The use of Cancer/Testis antigens to monitor levels of circulating malignant stem cells in Multiple Myeloma.	karen Shires
173	Minimal Residual Disease Measurement in Multiple Myeloma: Survey of Clinician Practices	Benjamin Derman
185	Urine immunofixation is not necessary for CR definition in myeloma patients with complete M protein molecule	Jakub Radocha
190	CD200 expression level is associated with outcome in multiple myeloma	lijuan chen
215	Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA	Jana Gregorova
244	Monitoring the cytogenetic architecture of minimal residual plasma cells indicates the therapy-induced clonal selection in multiple myeloma	yuting Yan
248	Comparison of minimal residual disease detection in multiple myeloma between SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry methods	Hiroyuki Takamatsu
249	Minimal residual disease assessment using EuroFlow in patients with relapsed/refractory multiple myeloma who received carfilzomib+lenalidomide+dexamethasone (KRD) therapy	Hiroyuki Takamatsu
259	IgH-V(D)J NGS Study on Non-CR patients with Negative MRD by Next Generation Flow	Naery Yang
264	Standardized minimal residual disease detection by next generation sequencing in multiple myeloma	Qiumei Yao
295	Use of Quantitative Immunoprecipitation Mass Spectrometry to Resolve the Complexity of Plasma Cell Populations in Multiple Myeloma	Brittney Howard
302	Minimal Residual Disease (MRD) ratio before and after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma.	Riccardo Boncompagni
369	Saliva-omics in Plasma Cell Disorders-proof of concept and potential as a non-invasive tool for monitoring disease burden and MRD status.	Ciara Tierney
401	Evaluation and Dilution Verification of the Optilite FreeliteTM Assay show discordant results at high serum free light chain concentrations	Terence A. Agbor
435	Upgraded standardized minimal residual disease detection by next generation sequencing in multiple myeloma	Qiumei Yao
458	Comparison of three different assays demonstrates heterogeneity in determination of serum free light chains - implications on diagnostic and therapeutic monitoring of multiple myeloma	Aneta Schieferdecker
461	Myeloma plasma cell Multiparametric Flow Cytometry (MFC) detection in autograft products of Newly Diagnosed Multiple Myeloma (NDMM).	Riccardo Boncompagni
479	Clinical relevance of Minimal residual Disease assessment by NGS in Multiple Myeloma	Joaquin Martinez-Lopez
541	Concordance Analysis of PET-CT and 10 Color MFC used for MRD assessment with other serological remission markers in Newly Diagnosed Multiple Myeloma patients Post-ASCT	Uday Yanamandra
546	Bone marrow lymphocytes reconstructive pattern in multiple myeloma patients after autologous transplant has no prognostic significance	Martin Stork
716	Recovery of policlonal immunoglobulins as a predictor factor of increased progression-free survival and overall survival in patients with multiple myeloma ineligible for ASCT	Julio Davila
751	Circulating tumor DNA in the peripheral blood as early predictor of clinical outcome in relapsed/ refractory multiple myeloma	Johannes M. Waldschmidt
788	Minimal residual disease and quality sample evaluation by Next Generation Flow cytometry in multiple myeloma patients: a Brazilian experience	ANNA BEATRIZ SALGADO
795	Comparison of PET Reconstruction Algorithms on Assessment and Quantification of FDG-PETCT Findings in Patients with Multiple Myeloma	Suzanne Arulogun
822	PROGNOSTIC SIGNIFICANCE OF RED BLOOD CELL DISTRIBUTION WIDTH (RDW) AND DIVERSE HEMOGRAM RATIOS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)	Sara Aida JimÃ©nez-JuliÃ
830	STANDARDIZATION OF HIGH SENSITIVITY MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA: AN EXPERIENCE IN TERTIARY CANCER CENTRE	Papagudi Subramanian
853	Post-transplant minimal residual disease assessment in Multiple myeloma	Anjali Mookerjee
856	Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy	Evangelos Terpos
858	Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy	Ioannis V. Kostopoulos
870	Changes in Serum B-Cell Maturation Antigen Levels Rapidly Predict Progression Free Survival among Multiple Myeloma Patients undergoing New Treatment	Sean Bujarski
872	Normalization of Serum B-cell Maturation Antigen Levels Predicts Progression Free and Overall Survival in Multiple Myeloma Patients Starting Treatment	Scott Jew

Multiple Myeloma Bone Disease

Multiple Myeloma Bone Disease - Poster Session I

Abstract Number	Poster Presentation	Lead Author
255	18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment	Sung-Hoon Jung
333	Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group	EIRINI KATODRITOU
501	Initial extramedullary myeloma impacts overall survival via affecting post progression survival	Hisashi Takei
584	Ixazomib inhibits osteoclastogenesis and promotes osteogenic differentiation in vitro	Daniele Tibullo
585	Imaging in Multiple Myeloma - Independent review perspective for IMWG 2016 response assessment	Jayant Narang
591	NONSECRETORY MUTIPLE MYELOMA. A RARE HEMATHOLOGIC ENTITY AND POSSIBLE MISDIAGNOSIS. A CASE REPORT WARNING	Antonio Abbadessa
624	Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma	Fumou Sun
652	COMPARISON OF RADIODIAGNOSTIC METHODS (CONVENTIONAL RADIOGRAPHY, LOW-DOSE COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING) WITH SELECTED MARKERS OF BONE METABOLISM AND BONE MARROW MICROENVIRONMENT	Petra Krhovska
746	Cryoablative Surgery for Patients with Radiotherapy Resistant Solitary Plasmacytoma: Report of Two Cases	Efrat Luttwak
878	New factors involved in the appearance of Mandibular Osteonecrosis by Bisphosphonates in Multiple Myeloma. A multicentric study.	Alicia SenÃn MagÃ¡n

Treatment of Newly Diagnosed Myeloma Transplant Eligible

Treatment of Newly Diagnosed Myeloma Transplant Eligible - Poster Session II

Abstract Number	Poster Presentation	Lead Author
135	Introducing Self Administration of Bortezomib (Velcade) to Myeloma Patients	Tanya Burton
182	Developing a support and information group for Myeloma patients and their carers in a private healthcare settingâ€™	Darren Simpson
205	Carfilzomib-based induction improves progression free survival and rate of minimal residual disease negativity following autologous transplant in high risk multiple myeloma patients: a retrospective analysis	Ricardo Parrondo
238	The prognostic impact of dynamic changing of cytogenetic abnormalities under the treatment options in multiple myeloma	Fan huishou
242	Real-world Outcomes of Chinese patients with high-risk Multiple Myeloma	Sui Weiwei
243	The impact of response kinetics following initial therapy for multiple myeloma in the era of novel agents	yuting Yan
280	Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis	NORIKO NISHIMURA
309	Examining the Association between Insurance Status as an Access to Care Proxy and 5-year Multiple Myeloma-Specific Survival in US Adults	Colleen Hallock
316	Tandem autologous stem cell transplantation in high-risk patients with newly diagnosed multiple myeloma: Feasibility and preliminary results.	Javier DE LA RUBIA
336	Bortezomib-based regimens for primary multiple myeloma patients in China: from 2006 to 2018	Zhen Cai
352	Selecting transplant in the elderly: validation of IMWG frailty score and Revised Myeloma Comorbidity Index compared to clinical judgment	ANGELO BELOTTI
397	Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma After Frontline Transplant: A Multicenter, Randomized, Phase 3 Study (AURIGA)	Thomas Lin
405	Bortezomib-Dexamethasone vs Bortezomib-Dexamethasone and chemotherapeutic agents in Transplant-Eligible Newly Diagnosed Myeloma	L Abril
427	Adaption of the Dexamethasone Symptom Questionnaire in a Multiple Myeloma Population: Item generation, content and face validity of the â€˜Steroid Symptom Questionnaire â€“ Multiple Myelomaâ€™ (SSQ-MM)	Tracy King
443	A phase I/II, open-label, prospective, multicenter study to evaluate the efficacy and safety of lower doses of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation: The KMM103 study	Chang Ki Min
444	Impact of autologous stem cell transplantation on renal response in multiple myeloma patients with advanced renal failure	Chang Ki Min
450	Impact of 18F-FDG PET/CT as a valuable prognostic tool for the newly diagnosed multiple myeloma with extramedullary disease	Dong Won Baek
469	Impact of t(11;14) on the outcome of autologous transplantation in Multiple Myeloma: A multiple centers retrospective analysis from China	wen gao
486	The differential presentation patterns and outcomes of young (AYA) myeloma patients... A single center two-decade experience	Mehmet Kocoglu
491	Impact of Regional Income and Insurance Status on Survival of Multiple Myeloma Patients: Autologous Stem Cell Transplant as an Equalizer	Kamal Chamoun
499	Polyclonal immunoglobulin recovery after autologous stem cell transplantation is an independent prognosis factor for survival in patients with multiple myeloma	Shuji Ozaki
505	Understanding the financial impact of cancer: Examining the â€˜COSTâ€™ Measure in the Australian context.	Kate White
524	Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival	Eva-Maria Haas
531	Relationship between exercise, fatigue levels and patient attitudes to exercise: The multiple myeloma patient. An integrative review.	Gail Wilmot
533	Strengthening the myeloma nursing network in Australia and New Zealand (ANZ): Leading best supportive care	Tracy King
538	Bortezomib, Liposome Doxorubicin and Dexamethasone (PDd) is Superior in Safety and Not Inferior in Efficiency to Bortezomib, Doxorubicin and Dexamethasone (PAd) As Induction Therapy in New-Diagnosed Multiple Myeloma Patients	Yan Shuang
547	COMMON REASONS FOR CHANGE OF CHEMOREGIMENS IN MULTIPLE MYELOMA: REAL WORLD, COMPARISON OF TWO TERTIARY CARE CENTERS	Pankaj Malhotra
580	Characteristics and Outcome of Relapsed Myeloma after Single Autologous Stem Cell Transplant: 20-year Experience.	Lalit Kumar
593	A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible	Philippe Moreau
600	Information needs of myeloma patients along the illness trajectory	Matthias Naegele
601	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma â€“ Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation	Charlotte Gran
604	BASELINE CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA: INDIAN PERSPECTIVE	GOPILA GUPTA
610	Long term remissions, late relapses and prolonged survival in patients with multiple myeloma before the era of novel agents	AIKATERINI MEGALAKAKI
633	Real-time prediction of myeloma clinical responses using an ex vivo, 3-dimensional culture system	Michael Chu
640	ALPINA: Real World Analysis of 1st line RVd treatment in Transplant Eligible & Transplant-non-Eligible MM patients with a focus on tolerability and efficacy	Ella Willenbacher
655	Eight versus four induction cycles of Carfilzomib, Thalidomide and Low-dose Dexamethasone: the Carthadex trial.	Ruth Wester
670	Impact of cytogenetics versus FISH detected t(11;14) in newly diagnosed multiple myeloma patients with upfront transplantation	Neeraj Saini
673	Modified risk stratification (MRS) for Multiple Myeloma- A simplified model using machine learning	Ritu Gupta
677	Patient Reported Outcome Measures in multiple myeloma: real-time rePorTing to improve care (My-PROMPT) - a pilot randomised controlled trial	Elizabeth Moore
679	Over 10 years relative median survival in MM patients â‰¤ 65 years with VGPR or better on 1st line treatment. Population-based data on patients diagnosed 2008-2018 from the Swedish Myeloma Registry	Cecilie Hveding Blimark
709	RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort	Amitoj Gill
714	Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)	Hilary Blacklock
722	A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)	Philippe Moreau
727	Early mortality in Transplant-eligible Multiple Myeloma patients in Latin America. An International Study of GELAMM.	Virginia Bove
743	Development of an Individualized, Supervised Exercise Intervention as Standard Care for Patients with Multiple Myeloma	Jennifer Nicol
744	A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide- Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)	Pieter Sonneveld
754	Assessing efficacy and tolerability of a modified lenalidomide/bortezomib/dexamethasone (VRd-28) regimen using weekly bortezomib in multiple myeloma	Cesar Rodriguez
783	NEGATIVE IMPACT OF HIGH LDH AT DIAGNOSIS ON OS, BUT NOT PFS, CAN BE OVERCOME BY AUTOLOGOUS STEM CELL TRANSPLANTATION	Guldane Cengiz Seval
808	Outcomes with different administration schedules of VRD as first-line therapy in multiple myeloma: a retrospective analysis	Joselle Cook
815	The Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM): Feasibility, acceptability, reliability and internal consistency.	Tracy King
817	Retrospective study on various peripheral blood stem cell collection regimens	NAOKI TAKEZAKO
823	Multiple myeloma and comorbidity: a population-based study	Ingigerdur Sverrisdottir
835	Once-Weekly 1.6mg/m2 Bortezomib BCD Regimen in Newly Diagnosed Multiple Myeloma: Better Response and Lower Incidence of Peripheral Neuropathy	Fangfang Li
840	Risk of developing Venous Thromboembolism in Multiple Myeloma; Based on current VTE risk assessment models : Impede VTE Score & IMWG guidelines	INES MARTINEZ ALFONZO

Treatment of Newly Diagnosed Myeloma Non-Transplant Eligible

Treatment of Newly Diagnosed Myeloma Non-Transplant Eligible - Poster Session II

Abstract Number	Poster Presentation	Lead Author
128	A review of diagnostic features of multiple myeloma in Sub-Saharan black subjects Africa.	DOMINIQUE PATRICIA KINGUE TATNOU
164	PROFILE AND TREATMENT OUTCOMES OF FILIPINO MULTIPLE MYELOMA PATIENTS MANAGED AT A TERTIARY INSTITUTION: A SIX-YEAR RETROSPECTIVE STUDY	Joy Ann de Castro
203	Phase 3 FIRST Trial in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Patients From Canada and the United States	Andrew Belch
213	PROGNOSTIC RELEVANCE OF THE PROPORTION OF RESIDUAL POLYCLONAL PLASMA CELLS IN THE DIAGNOSTIC BONE MARROW OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS MANAGED WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION	PRASHANT TEMBHARE
253	Multiple myeloma treatment patterns, outcomes, and costs during 2009-2016, identified with multiple data sources from a hospital district in Finland	Jonna Salonen
263	Significantly improved relative survival of patients with myeloma in Queensland with treatment advances	Dr Peter Mollee
305	Low Body Mass Index is a Predictor of Early Mortality in Patients with Newly Diagnosed Multiple Myeloma	Chia-Jen Liu
384	Post-Authorization Safety Study of Lenalidomide-Based vs Nonâ€“Lenalidomide-Based Treatment in Transplant-Ineligible Newly Diagnosed Multiple Myeloma	Michele Cavo
386	Association Between Costs of Care in Oncology Care Model (OCM)-Defined Episodes and Overall Survival in Multiple Myeloma	Cynthia Z Qi
403	Impact on efficacy of the dose and schedule of bortezomib in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.	Gladys Ibarra
417	UPSTAGING ISS AND R-ISS BY PLATELET COUNT: REAL-LIFE ANALYSIS OF 321 MM PATIENTS	Massimo Offidani
424	Quality of Life Assessment in Older Patients with Newly-Diagnosed Multiple Myeloma	Hira Mian
462	What do costly tests add to baseline profile? Diagnostic work up of Myeloma in resource constraint setting	RICHA ARORA
466	Improved Treatment Outcome of Transplant Ineligible Multiple Myeloma in the Era of Novel Agents: Experience from Tertiary Care Centre in North India	Soniya Nityanand
468	Prognostic impact of rapid involved light chain reduction in first line therapy with Bendamustine, Prednisone and Bortezomib (BPV) in myeloma patients	Tanja Holzhey
493	Impact of Early vs Late Relapse in Patients With Newly Diagnosed Multiple Myeloma Ineligible for Transplant: A Phase 3 FIRST Trial Subanalysis	Thierry Facon
554	Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between GDP/Capita, Access to Cancer Drugs, Patient Visits to the IMF Website and Mortality-to-Incidence Ratio as Proxy for Survival	Heinz Ludwig
570	PRESCRIPTION PATTERNS AND OUTCOMES OF FIRST-LINE THERAPY FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA REAL-LIFE PATIENTS ACCORDING TO AGE: A RETROSPECTIVE ANALYSIS OF THE 2012-2016 PERIOD	MarÃa JosÃ© Cejalvo
599	NEWLY-DIAGNOSED, NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS: DETERMINANTS OF CHOICE OF FIRST-LINE TREATMENT IN A SINGLE-CENTER.	Laura Paris
642	Outcome of elderly patients with newly diagnosed multiple myeloma depending on the eligibility for clinical trials: a single institution experience.	Natalia Tovar
660	Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction	Dr Peter Mollee
666	Treatment Pattern and Overall Survival in Newly Diagnosed Multiple Myeloma Patients who are not Eligible for Autologous Stem Cell Transplantation	Jianming He
759	The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma.	Nicole C. Foley
831	Lenalidomide-Related Diarrhea Correlates with Disease Control in Newly-Diagnosed Patients with Multiple Myeloma	Beth Faiman
852	Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant	Katharine Gries
881	Testing LBA	Heather Test
882	Treatment of Newly Diagnosed Multiple Myeloma: A Real-world Study in A Western Single Center of China	Yi Liao

Treatment of Previously Treated Myeloma

Treatment of Previously Treated Myeloma - Poster Session II

Abstract Number	Poster Presentation	Lead Author
119	Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)	Bethany Monteith
132	Consolidation following DPACE therapy improves outcomes in relapsed/refractory myeloma patients in the era of novel agents	Faouzi Djebbari
147	Marital Status and Survival in Patients with Multiple Myeloma: The Role of Marriage in the Management of Multiple Myeloma	Serajul Islam
155	A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma	Jack Khouri
159	The elevation of eosinophils could prolong the time to the next treatment in patients with RRMM who are treated with lenalidomide	Kazuhito Suzuki
170	The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study	Agoston Gyula Szabo
204	MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma	Olivier DECAUX
206	A â€˜real-worldâ€™ study of panobinostat, bortezomib and dexamethasone in a very heavily pre-treated population of myeloma patients	Sarah Bird
209	Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR	Thierry Facon
210	Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma	Jiri Minarik
227	Bortezomib Induced Peripheral Neuropathy: A Systematic Review of Phase III Trials	Tiffany Li
270	3-weekly Daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma	James Chim
276	Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma	Xavier Leleu
289	Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma	Katja Weisel
290	Health-Related Quality of Life With Pomalidomide + Dexamethasone + Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients	Donna Reece
291	OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma	Kosei Matsue
313	Angiotensin II receptor blockers might reduce a cardiotoxicity induced by carfilzomib: retrospective analysis of 17 cases	Takanori Fukuta
314	Weekly 20/56mg/mÂ² Carfilzomib, Lenalidomide and Dexamethasone until progression in Early Relapsed Refractory Multiple Myeloma	Cecile GRUCHET
315	Pomalidomide 3rd line versus 4th line for in Early Relapsed Refractory Multiple Myeloma	Cecile GRUCHET
331	Venetoclax for the Treatment of Multiple Myeloma: Outcomes Outside of Clinical Trials	M Hasib Sidiqi
348	A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines	Raija Silvennoinen
357	Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study	Roberto Mina
360	Progressive multifocal leukoencephalopathy after daratumumab in a patient post allo-HCT successfully treated with JC-virus specific donor lymphocytes	Max Steinhardt
367	Ex-Vivo 3D-Cultures of Patient-Derived Primary MM cells Retrospectively Predicts Treatment Clinical Outcomes in MM Patients	Kareem Azab
371	A Patient-Physician Tool to Improve CoMMunication in Relapsed Refractory Multiple Myeloma (RRMM)	Thomas Leblanc
380	Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma	E. Bridget Kim
382	Assessing the Effect of Pomalidomide or Carfilzomib Treatment on Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma	Shaloo Gupta
385	Examining Treatment Patterns, Patient Characteristics, and Outcomes Associated With Pomalidomide in Multiple Myeloma Following Lenalidomide Therapy	Machaon Bonafede
389	An SLR of Clinical and Real-World Evidence in Relapsed/Refractory Multiple Myeloma (RRMM) Studies to Inform Clinical Decision-Making in the US	Anna Forsythe
396	A Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma who have been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)	Nizar J. Bahlis
399	A Phase 3 Study of Carfilzomib and Dexamethasone (Kd) in Patients With Relapsed and Refractory Multiple Myeloma (MM) in China	Juan Du
400	Development and Evaluation of Methods for Early Relapse Detection in Multiple Myeloma Patients Treated with Bortezomib	Dean Bottino
407	Real World Data on the Safety and Efficacy of Pomalidomide as a Single Agent and in Combination with Corticosteroids in Relapsed and Refractory Multiple Myeloma	Tahani Atieh
414	Factors associated with the probability to skip subsequent lines of therapy: analysis of 321 Multiple Myeloma (MM) patients in a single tertiary centre	Massimo Offidani
432	Analysis of risk factors for lenalidomide-associated skin rash and desensitization protocol using prednisolone administration in patients with multiple myeloma	Shin Ohara
451	The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting	Hannah Cherniawsky
455	Retrospective analysis on 20 relapsed or refractory cases of multiple myeloma treated by panobinostat with subcutaneous bortezomib	Tohru Izumi
464	The comparison of Carfilzomib, and dexamethasone versus pomalidomide-based combination chemotherapy after a 2nd-line therapy in relapsed and refractory multiple myeloma patients	Ji Hyun Lee
474	Quality of life assessment in multiple myeloma patient and their caregivers.	Jill Burke
478	Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma	Yildiz Aydin
481	Quality of life of treatment for relapsed/refractory multiple myeloma: a systematic review	Maria Nassim
497	European Post-Authorization Safety Study of Patients With Relapsed or Refractory Multiple Myeloma Treated With Pomalidomide in a Real-World Setting	Barbara Gamberi
513	A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma.	Swetha Kambhampati
522	Comparing clinical trial data against a real world dataset â€“ progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatment	Jacken Waters
537	Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis	Meletios A. Dimopoulos
542	ICARIA-MM study: efficacy analysis according to prior lines of treatment	Sara Bringhen
556	Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM).	Julie Stakiw
563	The efficacy and safety profiles of carfilzomib based therapy in real world practice for patients with relapsed or refractory multiple myeloma	Min Ji Jeon
576	Real World Data on the Efficacy and Safety of Ixazomib Based Therapy in Multiple Myeloma: An Observational Study from China	Jing Li
586	Flow-Mediated Dilatation (FMD) and Aortic Blood Pressure May Predict Cardiovascular Adverse Events During Carfilzomib Therapy: A Prospective Study in Relapsed/Refractory Multiple Myeloma Patients	Efstathios Kastritis
590	Patient characteristics and treatment patterns in multiple myeloma by treatment administration route and disease status: EASEMENT observational study	Neil Rabin
632	Carfilzomib, Thalidomide and Dexamethasone (KTd) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study	Slavisa Ninkovic
662	Efficacy of intensive salvage regimen (VTD-PACE and DCEP regimen) in the era of novel agents.	Junichiro Nashimoto
667	ELOTUZUMAB PLUS POMALIDOMIDE OR LENALIDOMIDE IS ABLE TO ACHIEVE DURABLE â‰¥VGPR RESPONSES AMONG IMMUNOMODULATORY / PROTEASOME INHIBITOR REFRACTORY MYELOMA PATIENTS: A REPORT ON MULTICENTER EXPERIENCE FROM TURKEY	Meral Beksac
711	Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study	Saad Usmani
717	KD-PACE salvage therapy for aggressive relapsed multiple myeloma	Shelton Harrell
719	Retrospective Review of hyperammonemic encephalopathy due to multiple myeloma: clinical features and response to treatment	Priya Rajakumar
747	Results of the Daratumumab Monotherapy Early Access Treatment Protocol (EAP) in Patients from Brazil With Relapsed or Refractory Multiple Myeloma	Edvan de Queiroz CrusoÃ©
753	REAL-WORLD USE OF CARFILZOMIB THERAPY AMONG PATIENTS WITH EXISTING CARDIOVASCULAR MEDICAL HISTORY: AN ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY	Jo Caers
760	A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)	James Berenson
761	Treatment Patterns and Clinical Outcomes Across Consecutive Treatment Lines in Multiple Myeloma Patients: Single-Center Real World Experience.	Svetlana Trestman
766	A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/ Refractory Multiple Myeloma Patients	James Berenson
768	REAL-WORLD EVIDENCE OF THE USE OF CARFILZOMIB AND DEXAMETHASONE ACCORDING TO AGE SUBGROUP: AN INTERIM ANALYSIS FROM A PROSPECTIVE OBSERVATIONAL STUDY	Evangelos Terpos
775	Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA	Saad Usmani
784	Multi-agent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone and daratumumab (Pom-PAD-Dara) in relapsed/ refractory multiple myeloma	Xiang Zhou
790	REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED MULTIPLE MYELOMA	Gabrielle Lawson
793	DEMOGRAPHIC CHARACTERISTICS AND TREATMENT PATTERNS OF RELAPSE / REFRACTORY MULTIPLE MYELOMA PTS: CHARISMMA STUDY AND INSIGHT MM REGISTRY IN SPAIN	Enrique M Ocio
809	Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network	Martin Gramatzki
814	The addition of a HIV protease inhibitor to carfilzomib therapy in myeloma overcomes ABCB1-mediated drug resistance: a proof of concept	Rory Bennett
818	Therapy With Steroid-Containing Regimens in Myeloma Patients Can Result in Significantly Low Serum Cortisol Levels	Mark Cook
847	Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma (MM): Single center experience	RAVI KISHORE NARRA
859	MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS: ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRASPLANT (ASCT): EXPERIENCE OF TWO CENTERS	Villalobos MarÃa Teresa
861	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)	Leon Bernal
868	Relapsed/refractory multiple myeloma (R/R MM): a real-world overview of oral vs. IV/SC treatment cost and time burden in a Portuguese hospital	Henrique Coelho

Myeloma Transplant and Maintenance Strategies

Myeloma Transplant and Maintenance Strategies - Poster Session II

Abstract Number	Poster Presentation	Lead Author
139	Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE	Marc-A. Baertsch
195	The Quality of Life on Effect and the Cost of Tandem Transplantation in Multiple Myeloma Patients	Masato Komuro
241	Clinical Characteristics, Survival Outcomes and prognosis in 82 Immunoglobulin D Multiple Myeloma Patients: A Retrospective Single-Center Study	Liu Jiahui
262	The Princess Margaret Cancer Centre Experience: Transitioning to GCSF Alone for Stem Cell Mobilization in Myeloma Patients	Lauren Finlay
273	INTRAVENOUS BUSULFAN-MELPHALAN VS MELPHALAN AS PREPARATIVE REGIMEN FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF A CASE-CONTROL STUDY	MARGARITA BLANES
294	IMPROVEMENT OF EARLY MORTALITY AND LONG-TERM SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA BETWEEN 1970 AND 2015	Luis Gerardo RodrÃguez-Lobato
323	Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant.	M Hasib Sidiqi
327	Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. Impact of disease characteristics, disease status at transplant, and prior number of lines of therapy. Results of retrospective, multicentre Spanish study.	Javier DE LA RUBIA
342	Depth of Response and Outcomes by Initial Therapy Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma	Gunjan Shah
390	Effectiveness of Maintenance Treatment in Newly Diagnosed Multiple Myeloma (NDMM): Results of an SLR to Inform Clinical Decision-Making in the US	Anna Forsythe
438	Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving â‰¥VGPR following PAD induction in the Phase 2 PADIMAC study	Wei Yee Chan
453	LDH and Renal Function are Prognostic factors for Long-term Outcomes of Multiple Myeloma Patients undergoing Allogeneic Hematopoietic Stem Cell: a Cohort of 100 Recipients	Roni Shouval
463	Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM)	Martin Kaiser
471	A Prospective, Multicenter Phase II Study of Consolidation with Cyclophosphamide, Bortezomib and Dexamethasone (CVD) in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation; The KMM130 Study	Hyeon-Seok Eom
473	Evolving Risk Factors for Mortality, Progression, Myeloid Dysplasia and Survival in Large 2-Decade Single-Centre Autologous Transplant Cohort of Myeloma, Amyloidosis and related Plasma Cell Dyscrasia	James Cavet
495	Maintenance lenalidomide therapy following upfront autologous stem cell transplantation does not impact progression-free survival 2.	Danny Luan
503	Prolonged Lenalidomide Maintenace Therapy Improves the Quality and Deep of Response in Multiple Myeloma	Rafael Alonso FernÃ¡ndez
525	Interim Analysis of Indian Multicentre Phase II Randomized Study Comparing Three Subcutaneous Bortezomib-based Post Stem Cell Transplantation Consolidation/ Maintenance Regimens for Newly Diagnosed Multiple Myeloma Patients (IMPOSe-Bortecon) Study Number: 4905/2017	Uday Yanamandra
526	Health-related quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial	Meletios A. Dimopoulos
567	Cost of Autologous Hematopoietic Stem Cell Transplantation in Patients of Multiple Myeloma in a Tertiary Care Center in India	SIDDHARTH SHANKAR
578	Comparison of Granulocyte colony stimulating factor support versus antibiotic prophylaxis in autologous stem cell transplantation in multiple myeloma	Eva-Maria Haas
587	The Effect of PET/CT Deauville Criteria on Progression Free Survival and Overall Survival in Multiple Myeloma Patients Following Autologous Stem Cell Transplantation	Tulin Tuglular
597	Multiple Myeloma: Autologous Stem Cell Transplant in an aging population	Justin King
613	Natural killer cell alloreactivity is not beneficial in haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for multiple myeloma: results of a prospective phase 2 clinical trial	Catharina Van Elssen
630	Severe obesity does not worsen transplantation outcome in multiple myeloma	Zhubin Gahvari
641	Preemptive plerixafor based mobilization strategy in multiple myeloma patients for autologous stem cell transplantation	Surya Prakash Vadlamani
646	Interleukin-6 (IL-6) Blockade with Siltuximab Peri-Autologous Hematopoietic Stem Cell Transplantation (AHCT) May Reduce Symptom Burden by Altering the Cytokine Milieu in Older Patients with Multiple Myeloma (MM)	Gunjan Shah
649	Successful Pharmacokinetic (PK)-Directed Dosing of EvomelaÂ® (propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)	Gunjan Shah
663	Racial disparities in multiple myeloma patients with durable stringent complete response	Amin Benyounes
707	Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study	Efrat Luttwak
735	Reduced-dose melphalan (140 or 100 mg/m2) maintains efficacy and tolerability for multiple myeloma patients with advanced age or renal impairment undergoing autologous transplant	Maxwell Krem
772	Cognitive performance and perceived cognitive function in multiple myeloma patients treated with an autologous stem cell transplant: Results of the Brilliant Study	Melanie Tam

Other Plasma Cell Disorders and Amyloidosis

Other Plasma Cell Disorders and Amyloidosis - Poster Session II

Abstract Number	Poster Presentation	Lead Author
136	Screening for Gaucher disease in patients with plasma cell dyscrasias	Ioannis Ntanasis-Stathopoulos
150	Mass cytometry identifies expansion of double positive and PD-1+ T cell subsets in the tumor microenvironment of patients with POEMS syndrome.	Taxiarchis Kourelis
183	Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis â€“ a first report	Oliver Charles Cohen
202	Stabilization of amyloidogenic antibody light chains as a potential therapeutic strategy in AL amyloidosis	Gareth Morgan
211	Clinical and prognostic impact of circulating plasma cells on peripheral blood smears in multiple myeloma at presentation and during follow-up	Eva Laverdure
212	Clinical manifestations and outcomes of primary systemic AL amyloidosis: Chiang Mai University Experience	Ekarat Rattarittamrong
222	A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis	Larysa Sanchez
268	Red Flag Symptoms of AL Amyloidosis in Patients with Myeloma	Lisa Mendelson
272	Optimizing Patient Care Through the Use of Clinical Pathways and Standard Operating Procedures When Treating Patients with Systemic AL Amyloidosis	Dina Brauneis
287	Impact of tumor size and minimal marrow involvement on outcomes of patients with solitary plasmacytoma	Shotaro Chinen
317	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with WaldenstrÃ¶m macroglobulinemia.	Joshua Gustine
320	MGUS predicts worse prognosis in patients with coronary artery disease	Zhao Xu
332	Venetoclax For The Treatment of Translocation AL Amyloidosis	M Hasib Sidiqi
335	Changes in cardiac biomarkers with daratumumab therapy in patients with light chain amyloidosis	Ariel Kleman
341	The role of bone marrow biopsy in patients with plasma cell disorders; should all patients with a monoclonal protein be biopsied?	M Hasib Sidiqi
364	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis	Abdullah S. Al Saleh
374	Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission But With Persistent Renal Disease	Cindy Varga
406	Bortezomib self-injection is time-saving, cost-neutral and well received by patients with myeloma or AL amyloidosis: Results from the â€œSUBLIMEâ€ study	Simon Gibbs
415	Gene expression analysis reveals vitamin D regulates genes critical to oncogenesis in MYD88 mutated B cell lymphomas.	Tyler Kalajian
437	Development of a Participatory Patient Decision Aid for Patients with Multiple Myeloma	Beth Faiman
492	Risk of Progression Across Age and Race for Patients with Smoldering Multiple Myeloma	Sowjanya Vuyyala
504	Retrospective study of AL-amyloid patients with t(11;14) treated with daratumumab	Kelley Ratermann
508	BCMA expression in AL Amyloidosis	Susan Bal
515	Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity	Efstathios Kastritis
565	Increased mTOR activation in idiopathic multicentric Castleman disease	Daniel Arenas
569	Impact of Minimal Residual Negativity on Outcomes in Light Chain Amyloidosis	Surbhi Sidana
579	The impact on early diagnosis and survival outcome of M-protein screening-driven diagnostic approach to multiple myeloma in China: a cohort study	Jing Li
589	In Cardiac AL Amyloid a Higher BMI is Associated with a Lower Rate of Cardiac Response	So Yeon Kim
603	ESTIMATING THE GLOBAL EPIDEMIOLOGY OF AMYLOID LIGHT-CHAIN AMYLOIDOSIS WITH AN INCIDENCE-TO-PREVALENCE MODEL	Nicole Zhang
607	CLINICAL PROFILE AND OUTCOMES OF WALDENSTRÃ–M'S MACROGLOBULINEMIA FROM A TERTIARY CARE CENTER IN INDIA	GOPILA GUPTA
611	TREATMENT OF WALDENSTRÃ–M MACROGLOBULINEMIA (MW): EXPERIENCE IN REAL LIFE IN DIFFERENT CENTERS OF THE COMMUNITY OF MADRID (SPAIN)	ALICIA ROLDÃN PÃ‰REZ
634	POEMS SYNDROME: A single centre study of 68 patients and comparison of consolidation Autologous stem cell transplant(ASCT) versus non-ASCT cohorts.	Santosh kumar Chellapuram
669	Bortezomib, cyclophosphamide, and dexamethasone (CyBorD) as front-line treatment for systemic AL amyloidosis (AL): a real-world experience at a single centre	Yee Shuen Chong
678	Crystalcryoglobulinemia-induced kidney disease	Sophie Leflot
681	Primary Plasma Cell Leukemia: a retrospective series from a tertiary care center in India	VIKAS GARG
686	An Advanced Practice Provider-led, Outpatient Consult Clinic for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): The Cleveland Clinic Experience	Beth Faiman
696	Monoclonal gammopathy of clinical significance : about a case of nodular pulmonary amyloidosis.	GÃ©raldine Verstraete
699	Monoclonal Gammopathies and their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease	Anupama Kumar
700	MGCS : an IgG-lambda monoclonal gammopathy associated with renal failure, lung disease and cutis laxa	Pauline Storms
704	Clonal Heterogeneity and Immune Tumor Microenvironment in WaldenstrÃ¶m Macroglobulinemia	Jana Jakubikova
708	Oncogenic activity of human MYD88L265P mutation in mature B-cells in vivo	Tomasz Sewastianik
713	The PROMISE Study: A Nationwide Project for Predicting the Progression of Developing Myeloma in a High-Risk Screened Population	Annie Cowan
730	Outcome of first-line therapy in patients with systemic light-chain amyloidosis: A multicentre analysis	RubÃ©n FernÃ¡ndez
742	Insights into the Genomic Evolution of Ibrutinib Resistant Clones in WaldenstrÃ¶mâ€™s Macroglobulinemia	Cristina Jimenez
745	Identifying regulatory mutational densities within Waldenstromâ€™s Macroglobulinemia by whole genome sequencing	Gloria Chan
752	Distribution of circulating tumor cells in WaldenstrÃ¶mâ€™s Macroglobulinemia	Lian Xu
757	The BCR component SYK is activated by mutated MYD88 and the combined inhibition of SYK and BTK produces synthetic lethality in MYD88 driven B-cell lymphomas.	Manit Munshi
762	Mutated MYD88 regulates transcription of the pro-survival kinase HCK in MYD88 driven B-cell lymphomas.	Jiaji Chen
763	ACQUIRED HEMOPHILIA AND MONOCLONAL GAMMOPATHY OF HEMOSTASIC SIGNIFICANCE	FERNANDO ESCALANTE
764	Preliminary evidence of efficacy of venetoclax in relapsed and refractory AL amyloidosis.	Vikram Premkumar
769	Pilot study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with POEMS Syndrome	Angela Dispenzieri
771	Serum BCMA Levels Predict Outcomes for Patients with MGUS and Smoldering Multiple Myeloma (SMM)	Angela Dispenzieri
773	Blood mass spectrometry Detects Residual Disease Better than Standard Techniques in Immunoglobulin light chain amyloidosis	Angela Dispenzieri
780	Real-Time PET Imaging with Amyloid Fibril-Reactive Antibody CAEL-101 for Personalized AL Amyloidosis Immunotherapy	Jing Fu
820	Feasibility of heart transplantation for patients with amyloid cardiomyopathy accompanying extracardiac organ involvement	Inhwan Hwang
844	Peripheral neuropathy and monoclonal gammopathy of undetermined significance: A population-based study including 15,351 cases and 58,619 matched controls	SÃ¦mundur RÃ¶gnvaldsson
846	Minimal residual disease (MRD) in WaldenstrÃ¶m macroglobulinaemia (WM): Impact on survival outcomes with rituximab-based therapies.	Ruth De Tute
851	Dysregulation of the B-Cell Receptor Pathway Through Alternative Splicing in Waldenstromâ€™s Macroglobulinemia	Nickolas Tsakmaklis
855	Cell-Free DNA as Alternative to Bone Marrow CD19+ Selection for Diagnostic MYD88 L265P in Waldenstromâ€™s Macroglobulinemia	Maria Demos
860	Incidence of Amyloidosis in the US Veterans Health Administration	Tibor Kovacsovics
877	MYD88 and CXCR4 Mutation Rates by Allele-Specific PCR Compared with Diagnostic Next Generation Sequencing Panels in Patients with Waldenstromâ€™s Macroglobulinemia	Amanda Kofides

Workshop Organizers

Christopher Patterson
IMW 17 Secretariat

Dana Farber Cancer Institute
Mayor 548
450 Brookline Avenue
Boston, MA 02215
+1 617 632 6285

cpatterson1@partners.org

Follow the IMS

Become a Member Today

Housing & Registration

Accommodations

c/o SPARGO, Inc.
11208 Waples Mill Road
Suite 112
Fairfax, VA 22030 USA
888-788-1522 (US Toll free)
+ 1 703-449-6418 (International)

Reserve Now

Contact the IMS

International Myeloma Society

Lisa Sikkink, IMS Assistant

International Myeloma Society
Mayo Clinic
Siebens 6-60
200 First Street SW
Rochester, MN 55905
+1 507 284 3725

adminassistant@myelomasociety.org

Privacy Policy

Thank you!

Poster Presentations

POSTER SESSION I - FRIDAY, SEPTEMBER 13, 2019 - 6:30 to 8:00 PM - HYNES AUDITORIUM

POSTER SESSION II - SATURDAY, SEPTEMBER 14, 2019 - 12:30 to 2:00 PM – HYNES AUDITORIUM

Multiple Myeloma Genomics

Multiple Myeloma Genomics - Poster Session I